LDN-27219Tgases inhibitor CAS# 312946-37-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 312946-37-5 | SDF | Download SDF |
| PubChem ID | 1150683 | Appearance | Powder |
| Formula | C20H16N4O2S2 | M.Wt | 408.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 125 mg/mL (306.00 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-(4-oxo-3,5-diphenylthieno[2,3-d]pyrimidin-2-yl)sulfanylacetohydrazide | ||
| SMILES | C1=CC=C(C=C1)C2=CSC3=C2C(=O)N(C(=N3)SCC(=O)NN)C4=CC=CC=C4 | ||
| Standard InChIKey | WLBUICQBNZXIDJ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H16N4O2S2/c21-23-16(25)12-28-20-22-18-17(15(11-27-18)13-7-3-1-4-8-13)19(26)24(20)14-9-5-2-6-10-14/h1-11H,12,21H2,(H,23,25) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Transglutaminase 2 (TG2) inhibitor (IC50 = 0.25 μM). Binds at GTPase site; reversible. |
LDN-27219 Dilution Calculator
LDN-27219 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.448 mL | 12.2399 mL | 24.4798 mL | 48.9596 mL | 61.1995 mL |
| 5 mM | 0.4896 mL | 2.448 mL | 4.896 mL | 9.7919 mL | 12.2399 mL |
| 10 mM | 0.2448 mL | 1.224 mL | 2.448 mL | 4.896 mL | 6.12 mL |
| 50 mM | 0.049 mL | 0.2448 mL | 0.4896 mL | 0.9792 mL | 1.224 mL |
| 100 mM | 0.0245 mL | 0.1224 mL | 0.2448 mL | 0.4896 mL | 0.612 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
LDN-27219 is a reversible and slow-binding inhibitor of tissue transglutaminase (TGases) with IC50 value of 250nM for TGase 2 [1, 2].
LDN-27219 is discovered as a moderately potent inhibitor of TGase. It shows inhibitory activity against hTGase with IC50 value of 0.6μM. LDN-27219 is also a selective inhibitor. It has no effect on Factor XIIIa or caspase 3 at concentration up to 50μM. Besides that, LDN-27219 is found to be mutually exclusive inhibitors with GTP which is an allosteric inhibitor of TGase. It binds at sites other than the GTP site or the active site of the enzyme. The mechanism of LDN-27219 is also not similar with GTP. It has a modest effect on the binding of calcium. Moreover, it is found that LDN-27219 is a competitive inhibitor of the hTGase-catalyzed hydrolysis of Z-Pro-Gln-Ala-Trp [1].
References:
[1] Case A, Stein R L. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry, 2007, 46(4): 1106-1115.
[2] Duval E, Case A, Stein R L, et al. Structure–activity relationship study of novel tissue transglutaminase inhibitors. Bioorganic & medicinal chemistry letters, 2005, 15(7): 1885-1889.
- TCS JNK 5a
Catalog No.:BCC5148
CAS No.:312917-14-9
- Raucaffricine
Catalog No.:BCN4653
CAS No.:31282-07-2
- Hygromycin B
Catalog No.:BCC1204
CAS No.:31282-04-9
- Indacaterol
Catalog No.:BCC1650
CAS No.:312753-06-3
- gamma-Mangostin
Catalog No.:BCN5228
CAS No.:31271-07-5
- THIQ
Catalog No.:BCC7539
CAS No.:312637-48-2
- SKI II
Catalog No.:BCC5029
CAS No.:312636-16-1
- Tetrahydrocannabivarin
Catalog No.:BCN6935
CAS No.:31262-37-0
- IQ 3
Catalog No.:BCC8093
CAS No.:312538-03-7
- Cimigenol-3-one
Catalog No.:BCN7430
CAS No.:31222-32-9
- Eucalyptin
Catalog No.:BCN5227
CAS No.:3122-88-1
- Sideroxylin
Catalog No.:BCN5226
CAS No.:3122-87-0
- Arjunic acid
Catalog No.:BCN5229
CAS No.:31298-06-3
- Estradiol Cypionate
Catalog No.:BCC4477
CAS No.:313-06-4
- Aristolochic acid A
Catalog No.:BCN6262
CAS No.:313-67-7
- ICA 121431
Catalog No.:BCC6358
CAS No.:313254-51-2
- Regadenoson
Catalog No.:BCC6438
CAS No.:313348-27-5
- Reversan
Catalog No.:BCC7764
CAS No.:313397-13-6
- VU 590 dihydrochloride
Catalog No.:BCC7803
CAS No.:313505-85-0
- T0070907
Catalog No.:BCC2261
CAS No.:313516-66-4
- INH1
Catalog No.:BCC6040
CAS No.:313553-47-8
- Bombesin
Catalog No.:BCC5708
CAS No.:31362-50-2
- PD 118057
Catalog No.:BCC7499
CAS No.:313674-97-4
- 13-Oxo-9,11-octadecadienoic acid
Catalog No.:BCC8437
CAS No.:31385-09-8
Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.[Pubmed:17240993]
Biochemistry. 2007 Jan 30;46(4):1106-15.
Tissue transglutaminase (TGase) is a Ca2+-dependent enzyme that catalyzes cross-linking of intracellular proteins through a mechanism that involves isopeptide bond formation between Gln and Lys residues and is allosterically regulated by GTP. TGase is thought to play a pathogenic role in neurodegenerative diseases by promoting aggregation of disease-specific proteins that accumulate as part of these disorders. Given the role that TGase plays in neurodegenerative disorders, we initiated a research program to discover inhibitors of this enzyme that might ultimately be developed into therapeutic agents. To identify such inhibitors, we screened 110,000 druglike compounds for their ability to inhibit TGase [Case, A., et al. (2005) Anal. Biochem. 338, 237-244]. In this paper, we report the kinetics of interaction of human TGase with one of the inhibitors that we identified, LDN-27219. We found that this compound is a reversible, slow-binding inhibitor that appears not to bind at the enzyme's active site but rather at the enzyme's GTP site, or a site that regulates binding of GTP. Interestingly, the potency and kinetics of inhibition are dependent on substrate structure and suggest a novel mechanism of inhibition that involves differential binding of LDN-27219 to multiple conformational states of this enzyme.
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.[Pubmed:22224594]
J Med Chem. 2012 Feb 9;55(3):1021-46.
Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington's disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.
Structure-activity relationship study of novel tissue transglutaminase inhibitors.[Pubmed:15780627]
Bioorg Med Chem Lett. 2005 Apr 1;15(7):1885-9.
Thieno[2,3-d]pyrimidin-4-one acylhydrazide derivatives were discovered as moderately potent inhibitors of TGase 2 (tissue transglutaminase) utilizing a fluorescence-based assay that measured TGase 2 catalyzed incorporation of the dansylated Lys derivative alpha-N-Boc-Lys-CH(2)-CH(2)-dansyl into the protein substrate N,N-dimethylated-casein. A SAR study revealed that the acylhydrazide thioether side-chain and the thiophene ring were critical to inhibitory activity.
